인슐린 펌프 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 시스템 아키텍처별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Insulin Pump Market Summary

The global insulin pump market size was valued at USD 7.2 billion in 2025 and is projected to grow from USD 7.8 billion in 2026 to USD 13.1 billion by 2033, growing at a CAGR of 7.8% from 2026 to 2033. North America insulin pump market held the largest share of 45.4% of the global market in 2025. The market expansion is primarily driven by the growing elderly population, rising diabetes incidence, and increasing obesity prevalence.

Companies are developing next-generation insulin pumps with advanced technology to enhance compliance and integration with IT devices, further driving market growth. Innovations such as home infusion therapy and artificial pancreas technology are expected to create significant growth opportunities in the near future. Additionally, as insulin pumps gain popularity, markets in both developed and developing countries are expanding. An increase in the incidence of diabetes due to aging, obesity, and an unhealthy lifestyle is one of the factors contributing to the growth of the market. Obesity is a major factor causing diabetes, leading to increased incidences of diabetes-associated ophthalmic disorders. Risk factors, such as obesity, smoking, and high cholesterol, are expected to boost the prevalence of type II diabetes. According to the World Health Organization (WHO), recent global projections indicate that more than half of the world's adult population (approximately 3.8 billion people) could be living with overweight or obesity by 2050 if current trends continue.

Furthermore, there is a notable increase in the number of elderly individuals prone to developing diabetic neuropathy. The geriatric demographic is particularly vulnerable due to factors such as longer diabetes duration, decreased nerve regeneration capacity, and comorbidities that can exacerbate neuropathic symptoms. As the global population ages, the World Health Organization (WHO) predicts that the number of people aged 60 years and older will increase to 1 in 6 by 2030, rising from 1 billion in 2020 to 1.4 billion recently. The global population of people aged 60 years and older is expected to double to 2.1 billion by 2050, with individuals aged 80 years or older set to triple to 426 million. This demographic shift will lead to a higher likelihood of chronic conditions like diabetes and peripheral neuropathy, increasing the risk of diabetic neuropathy among seniors.

The insulin pump industry growth is anticipated to be driven by the technological advancements and manufacturers competing for product approval in key application area drives the market forwards. As more companies receive FDA approval, their adoption has notably increased. For instance, in April 2023, the FDA approved the Medtronic MiniMed 780G System, an advanced automated insulin delivery system for individuals aged 7 and older with type 1 diabetes. It is the world's first insulin pump with 'Meal Detection Technology'. This system uses continuous glucose monitoring (CGM) to track glucose levels and automatically adjusts insulin delivery. It includes a glucose sensor, wireless data transmission, and a smart insulin pump. Clinical trials and real-world evidence confirm its safety and effectiveness in managing diabetes, enhancing users' glucose control and quality of life. With the anticipated expansion of the insulin pump market and supported benefits such as better blood sugar control and improved quality of life, insulin pumps are poised to significantly empower individuals with diabetes, leading to healthier and more satisfying lifestyles.

"Mealtimes prove to be one of the biggest challenges for people living with type 1 diabetes and now for the first time, the MiniMed 780G system addresses this unmet need with automatic, real-time insulin corrections"

Key Professional at Medtronic plc

Increasing government initiatives for global awareness about medicare policies and the management of diabetes are also fueling market growth. Furthermore, there has been a rise in healthcare spending and an increase in the demand for improved tubeless insulin pumps that are both discreet and user-friendly. This is expected to drive market growth during the forecast period.

"We launched this unique contest in the community to better understand how patients describe diabetic nerve pain of their feet in their own terms.

By redefining the symptoms using their own words, our goal is to help diabetic peripheral neuropathy patients and their health care providers start using common language to talk about their symptoms, fostering more productive conversations around diagnosis, disease management and potential solutions."

Dr. Lizandra Marcondes, Head Medical Affairs Averitas Pharma

Innovations in integrating advanced technology and improving patient outcomes is driving market growth. The latest developments include the creation of closed-loop systems, also known as artificial pancreas systems, which automate insulin delivery based on real-time glucose monitoring. With their seamless integration with continuous glucose monitoring (CGM) technology and demonstrated effectiveness in blood sugar management, insulin pumps are becoming essential tools in the fight against diabetes. Systems such as a pump connected to an automated insulin delivery (AID) system, paired with a connected insulin pen or smart pen cap, enhance diabetes management. When combined with a powerful continuous glucose monitor (CGM) sensor, this technology offers precise and efficient blood glucose control. Further, the incorporation of wireless connectivity and mobile app integration allows for seamless data tracking and remote monitoring, providing healthcare providers with valuable insights into patient management. Moreover, advancements in pump design, such as smaller, more discreet devices and pain-free insertion techniques, are increasing patient comfort and adherence.

Global Insulin Pump Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis on the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the global insulin pump market report on the basis of product, system architecture, end use and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Tubed Pump
• Tubeless Insulin Pump
• System Architecture Outlook (Revenue, USD Million, 2021 - 2033)
• Open-loop Systems
• Closed-loop Systems
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Homecare
• Hospitals & Care Providers
• Region Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. System Architecture
  • 1.2.3. End-use
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. End-use outlook
• 2.3. Regional outlook
• 2.4. Competitive Insights

Chapter 3. Insulin Pump Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. High prevalence of diabetes and associated disorders
    • 3.2.1.2. Technological advancements
    • 3.2.1.3. Increasing adoption of insulin pumps
    • 3.2.1.4. Increase in number of product approvals
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High-cost barriers
    • 3.2.2.2. Stringent regulatory approvals
• 3.3. Insulin Pump Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape

Chapter 4. Insulin Pump Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Insulin Pump Market: Product Movement Analysis
• 4.3. Insulin Pump Market by Product Outlook (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 4.5. Tubed Pump
  • 4.5.1. Tubed Pump Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Tubeless Insulin Pump
  • 4.6.1. Tubeless Insulin Pump Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Insulin Pump Market: System Architecture Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Insulin Pump Market: System Architecture Movement Analysis
• 5.3. Insulin Pump Market by System Architecture Outlook (USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 5.5. Open-loop Systems
  • 5.5.1. Open-loop Systems Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Closed-loop Systems
  • 5.6.1. Closed-loop Systems Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Insulin Pump Market: End-use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Insulin Pump Market: End-use Movement Analysis
• 6.3. Insulin Pump Market by End-use Outlook (USD Million)
• 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 6.5. Homecare
  • 6.5.1. Homecare Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Hospitals & Care Providers
  • 6.6.1. Hospitals & Care Providers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Insulin Pump Market: Regional Estimates & Trend Analysis

• 7.1. Regional Dashboard
• 7.2. Regional Insulin Pump Market Movement Analysis
• 7.3. Insulin Pump Market: Regional Estimates & Trend Analysis by Product & End-Use
• 7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 7.5. North America
  • 7.5.1. North America Insulin Pump Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.2. U.S.
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Reimbursement Scenario
    • 7.5.2.5. U.S. Insulin Pump Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.3. Canada
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Reimbursement Scenario
    • 7.5.3.5. Canada Insulin Pump Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.4. Mexico
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Competitive Scenario
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. Reimbursement Scenario
    • 7.5.4.5. Mexico Insulin Pump Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.5. Europe
  • 7.5.6. Europe Insulin Pump Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.7. UK
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Competitive Scenario
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. Reimbursement Scenario
    • 7.5.7.5. UK Insulin Pump Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.8. Germany
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Competitive Scenario
    • 7.5.8.3. Regulatory Framework
    • 7.5.8.4. Reimbursement Scenario
    • 7.5.8.5. Germany Insulin Pump Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.9. France
    • 7.5.9.1. Key Country Dynamics
    • 7.5.9.2. Competitive Scenario
    • 7.5.9.3. Regulatory Framework
    • 7.5.9.4. Reimbursement Scenario
    • 7.5.9.5. France Insulin Pump Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.10. Italy
    • 7.5.10.1. Key Country Dynamics
    • 7.5.10.2. Competitive Scenario
    • 7.5.10.3. Regulatory Framework
    • 7.5.10.4. Reimbursement Scenario
    • 7.5.10.5. Italy Insulin Pump Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.11. Spain
    • 7.5.11.1. Key Country Dynamics
    • 7.5.11.2. Competitive Scenario
    • 7.5.11.3. Regulatory Framework
    • 7.5.11.4. Reimbursement Scenario
    • 7.5.11.5. Spain Insulin Pump Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.12. Denmark
    • 7.5.12.1. Key Country Dynamics
    • 7.5.12.2. Competitive Scenario
    • 7.5.12.3. Regulatory Framework
    • 7.5.12.4. Reimbursement Scenario
    • 7.5.12.5. Denmark Insulin Pump Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.13. Sweden
    • 7.5.13.1. Key Country Dynamics
    • 7.5.13.2. Competitive Scenario
    • 7.5.13.3. Regulatory Framework
    • 7.5.13.4. Reimbursement Scenario
    • 7.5.13.5. Sweden Insulin Pump Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.14. Norway
    • 7.5.14.1. Key Country Dynamics
    • 7.5.14.2. Competitive Scenario
    • 7.5.14.3. Regulatory Framework
    • 7.5.14.4. Reimbursement Scenario
    • 7.5.14.5. Norway Insulin Pump Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific Insulin Pump Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Reimbursement Scenario
    • 7.6.2.5. Japan Insulin Pump Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Reimbursement Scenario
    • 7.6.3.5. China Insulin Pump Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Competitive Scenario
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. Reimbursement Scenario
    • 7.6.4.5. India Insulin Pump Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.5. South Korea
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Competitive Scenario
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Reimbursement Scenario
    • 7.6.5.5. South Korea Insulin Pump Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.6. Australia
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Competitive Scenario
    • 7.6.6.3. Regulatory Framework
    • 7.6.6.4. Reimbursement Scenario
    • 7.6.6.5. Australia Insulin Pump Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.7. Thailand
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Competitive Scenario
    • 7.6.7.3. Regulatory Framework
    • 7.6.7.4. Reimbursement Scenario
    • 7.6.7.5. Thailand Insulin Pump Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. Latin America
  • 7.7.1. Latin America Insulin Pump Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. Reimbursement Scenario
    • 7.7.2.5. Brazil Insulin Pump Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Reimbursement Scenario
    • 7.7.3.5. Argentina Insulin Pump Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.8. Middle East & Africa
  • 7.8.1. Middle East & Africa Insulin Pump Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Competitive Scenario
    • 7.8.2.3. Regulatory Framework
    • 7.8.2.4. Reimbursement Scenario
    • 7.8.2.5. South Africa Insulin Pump Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Competitive Scenario
    • 7.8.3.3. Regulatory Framework
    • 7.8.3.4. Reimbursement Scenario
    • 7.8.3.5. Saudi Arabia Insulin Pump Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Competitive Scenario
    • 7.8.4.3. Regulatory Framework
    • 7.8.4.4. Reimbursement Scenario
    • 7.8.4.5. UAE Insulin Pump Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Competitive Scenario
    • 7.8.5.3. Regulatory Framework
    • 7.8.5.4. Reimbursement Scenario
    • 7.8.5.5. Kuwait Insulin Pump Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Market Participant Categorization
• 8.2. Company Market Share Analysis, 2025
• 8.3. Key Company Profiles
  • 8.3.1. Medtronic
    • 8.3.1.1. Company overview
    • 8.3.1.2. Financial performance
    • 8.3.1.3. Product benchmarking
    • 8.3.1.4. Strategic initiatives
  • 8.3.2. F. Hoffmann-La Roche AG
    • 8.3.2.1. Company overview
    • 8.3.2.2. Financial performance
    • 8.3.2.3. Product benchmarking
    • 8.3.2.4. Strategic initiatives
  • 8.3.3. Tandem Diabetes Care, Inc.
    • 8.3.3.1. Company overview
    • 8.3.3.2. Financial performance
    • 8.3.3.3. Product benchmarking
    • 8.3.3.4. Strategic initiatives
  • 8.3.4. Insulet Corporation
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Ypsomed
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Sanofi S.A.
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Sooil development
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Jiangsu Delfu Co., Ltd.
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Cellnovo Ltd
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Valeritas, Inc
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives